Serina Therapeutics Inc (SER)
| Market Cap | 67.31M |
| Revenue (ttm) | 3.15M |
| Net Income (ttm) | -890,146 |
| Shares Out | 8.41M |
| EPS (ttm) | 1.25 |
| PE Ratio | 6.43 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,134 |
| Open | 8.69 |
| Previous Close | 8.68 |
| Day's Range | 8.00 - 9.05 |
| 52-Week Range | 7.86 - 32.14 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2024 |
About SER
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alab... [Read more]
News
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
HUNTSVILLE, May 14, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technolo...
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
- Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development - HUNTSVILLE, AL, April 17, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (NYSE Am...
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
HUNTSVILLE, Ala., March 26, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson'...
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its...
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AgeX Therapeut...
AgeX Therapeutics Reports Third Quarter 2023 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...
Shareholder Alert: Ademi LLP investigates whether AgeX Therapeutics, Inc. has obtained a Fair Price in its transaction with Serina
MILWAUKEE , Aug. 30, 2023 /PRNewswire/ -- Ademi LLP is investigating AgeX (NYSE American: AGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Serina. Click...
AGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AgeX Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AgeX Therapeutics, Inc. (NYSE: AGE) and Serina Therapeutics, Inc. is fair to AgeX share...
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
HUNTSVILLE, Ala. & ALAMEDA, Calif.--(BUSINESS WIRE)--Serina Therapeutics, Inc. (“Serina”), a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment o...
AgeX Therapeutics Reports Second Quarter 2023 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 24, 2023...
AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 21, 2023...
AgeX Therapeutics Announces Appeal of NYSE American Determination
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on May 17...
CORRECTING and REPLACING NYSE American to Commence Delisting Proceedings Against AgeX Therapeutics, Inc. (AGE)
NEW YORK--(BUSINESS WIRE)--Headline of release should read: NYSE American to Commence Delisting Proceedings Against AgeX Therapeutics, Inc. (AGE) (instead of NYSE American to Suspend Trading Immediate...
NYSE American to Suspend Trading Immediately in AgeX Therapeutics, Inc. (AGE) and Commence Delisting Proceedings
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of ...
AgeX Therapeutics Reports First Quarter 2023 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...
AgeX Therapeutics Receives Stock Exchange Deficiency Letter
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April...
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on Nove...
AgeX Therapeutics Reports Third Quarter 2022 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and o...
AgeX Therapeutics Reports Second Quarter 2022 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...
Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joann...
Early-Stage Investments for Turkish Metaverse Platform MetaAge Nears $1-Million Mark
ISTANBUL--(BUSINESS WIRE)--MetaAge, a metaverse platform based on the Solana Blockchain, has drawn almost $1 million in early-stage investments, project managers said this week. Currently, under devel...
AgeX Therapeutics Reports First Quarter 2022 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...
AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...